✦ LIBER ✦

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

✍ Scribed by Henry Q. Xiong; Gauri R. Varadhachary; Joan C. Blais; Kenneth R. Hess; James L. Abbruzzese; Robert A. Wolff

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 96 KB
Volume: 113
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.23810

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase 2 study of irinotecan p

Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer

✍ Ji-Youn Han; Dae Ho Lee; Jung Eun Song; Sung Young Lee; Hyae Young Kim; Heung Ta 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 1 views

Weekly docetaxel with either gemcitabine

Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma : Phase II trials of the Minnie Pearl Cancer Research Network

✍ John D. Hainsworth; Howard A. Burris III; Frederic T. Billings III; James E. Bra 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 3 views

Exemestane versus anastrozole as front-l

Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer : Final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial

✍ Antonio Llombart-Cussac; Amparo Ruiz; Antonio Antón; Agustí Barnadas; Silvia Ant 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 1 views

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati